Objectives: ICLPS, which investigated the achievement of low-density lipoprotein cholesterol (LDL-C) targets in patients receiving lipid-lowering therapy (LLT) in countries outside of Western Europe, demonstrated that dyslipidaemia management was suboptimal. A secondary objective of ICLPS was to investigate healthcare consumption, and these data are presented here. Methods: Patients (n=9049) receiving LLT for ≥3 months who had had their LDL-C value measured on stable LLT in the previous 12 months were included in this cross-sectional observational study conducted between August 2015 and August 2016 in 18 countries in Eastern Europe, Asia, Africa, the Middle-East and Latin America. Data on healthcare resource consumption in the previous 12 months were collected for each patient during a single visit. Data were presented using descriptive statistics. Mixed categorical models were used to identify patient and environmental factors associated with undesired healthcare consumption (≥1 hospitalisation for a cardiovascular reason or ≥1 visit to the emergency room [ER]). Results: Of 20.1% of patients with ≥1 confirmed hospitalisation, 7.9% had hospitalisation for cardiovascular reasons and 35.2% had ≥1 hospitalisation in the intensive care unit (cardiovascular and non-cardiovascular reasons). Overall, 13.8% of patients had ≥1 ER visit. Undesired healthcare consumption was observed in 18.7% of patients (27.8%, 7.7%, 7.7% and 13.2% for very-high, high, moderate and low cardiovascular risk patients, respectively). Factors that increased the rate of undesired healthcare consumption (P<0.05) included being at very-high cardiovascular risk, certain cardiovascular risk factors (hypertension, smoking) and factors that make LDL-C management more difficult (statin intolerance, comorbidities and chronic medication). Conclusions: Undesired healthcare consumption was observed in patients with dyslipidaemia on stable LLT from countries outside of Western Europe, and its rate was increased in patients at very-high cardiovascular risk or who were ‘difficult to treat’. More effective dyslipidaemia management is needed to improve clinical outcomes and reduce healthcare consumption in this patient group.
Annemans, L., Azuri, J., Al-Rasadi, K., Al-Zakwani, I., Daclin, V., Mercier, F., & Danchin, N. (2018). PCV96 - HEALTHCARE RESOURCE UTLISATION IN PATIENTS ON LIPID-LOWERING THERAPIES OUTSIDE OF WESTERN EUROPE: FINDINGS OF THE INTERNATIONAL CHOLESTEROL MANAGEMENT PRACTICE STUDY (ICLPS). Value in Health, 21, S108–S109. https://doi.org/10.1016/j.jval.2018.09.641